KRAS and pancreatic neoplasm: Furthermore, a recent genome-scale CRISPR-Cas9 screen in KRAS-mutant pancreatic or lung cancer cell lines in the presence or absence of the MEK inhibitor trametinib unveiled FRA1 knock-out as a sensitizer to MEK inhibition in 2 out of 5 pancreatic cancer cell lines, but none of the 5 lung cancer cells [72].